Related Experiment Video

Updated: Jun 23, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Molecular targets of breast cancer: AKTing in concert

Alakananda Basu1

  • 1Department of Molecular Biology & Immunology, University of North Texas Health Science Center, Fort Worth, Texas, 76107.

Breast Cancer : Basic and Clinical Research
|May 12, 2009
PubMed

Insights

The Akt signaling pathway is crucial in breast cancer development and treatment resistance. Understanding its activation by various pathways can lead to improved therapeutic strategies for this disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Breast cancer remains a leading cause of death despite diagnostic and therapeutic advancements.
  • Aberrant signaling pathways are key drivers of breast cancer development and progression.
  • The Akt signaling pathway is frequently implicated in breast cancer, correlating with poor prognosis and treatment resistance.

Purpose of the Study:

  • To review recent literature on the role of Akt signaling in breast cancer.
  • To discuss how Akt activation by various pathways contributes to tumorigenesis.
  • To explore the contribution of Akt signaling to resistance against current breast cancer therapies.

Main Methods:

  • Literature review of recent studies on Akt signaling in breast cancer.
  • Analysis of signaling pathways that regulate Akt activity.
  • Examination of Akt's role in hormonal and chemotherapy resistance.

Main Results:

  • Akt pathway activation is associated with increased breast cancer development and progression.
  • Deregulated hormones, growth factors, and oncogenes frequently activate Akt in breast cancer.
  • Akt pathway activation confers resistance to established hormonal and chemotherapy treatments.

Conclusions:

  • Targeting the Akt signaling pathway presents a promising strategy for overcoming breast cancer treatment resistance.
  • Further elucidation of Akt-regulating pathways is essential for developing novel and effective breast cancer therapies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...